2023-03-28 09:35:39 ET
- SOPHiA GENETICS ( NASDAQ: SOPH ) said that Acutis Diagnostics will use SOPHiA DDM to develop a new genomic test.
- To create the this next-generation sequencing (NGS) test, Acutis will pair SOPHiA DDM for Hereditary Cancers Solution with their laboratory analysis technologies.
- The companies noted that the test will support genomic screening for patient enrollment in cancer trials and retrospective analyses to help explain clinical outcomes and drug target discovery.
For further details see:
Acutis to use SOPHiA's technology to develop next-gen sequencing test